CAPP3: a randomized dose finding non inferiority study of aspirin to prevent cancer in Lynch Syndrome

Lead Researcher: Professor Finlay Macrae

Institution: The Royal Melbourne Hospital

Funding: $290,340.50

Funding Duration: 2016 – 2018

‍

The Research

A trial to establish whether lower doses of aspirin are equally effective for cancer prevention making public health messages uniform across cardiovascular disease and cancer.

‍